Erasca Inc (ERAS): Fair Value Consensus
Erasca, Inc. (ERAS) is implementing energy saving and air purification in its centers in accordance with ESG standards. While the development of cancer drugs is independent of economic cycles, the company is vulnerable to investment shortages at the start, which currently stands at 23.65. The startup also strictly controls the disposal of hazardous substances in its laboratories. This price chart illustrates the market dynamics of this asset.
Analytical breakdowns for Erasca Corp (ERAS)
Erasca, Inc. (ERAS) pricing power potential within the inelastic demand segment for RAS-mutation therapies is reflected in the weighted average price target, fixed at 23.65. This indicator aggregates Wall Street analyst forecasts, measuring the business's fair value through the lens of expected cash flows, which allows investors to detect negative trends ahead of official credit rating revisions.
